Breaking News

Eurofins To Combine Businesses

April 2, 2014

Bio-analytical testing and genomic services becomes Eurofins Genomics

Eurofins Scientific is combining its bio-analytical testing and genomic services to provide a complete suite of services. Eurofins MWG Operon, a provider of genomic services, and Eurofins Medigenomix, the Group’s competence center for applied solutions in DNA & RNA analysis, will be brought together under the brand name Eurofins Genomics.
 
Eurofins Genomics will operate R&D and production sites in the U.S. in Huntsville, AL and Louisville, KY, as well as in Ebersberg, Germany, Bangalore, India, and Tokyo, Japan.
 
Bruno Poddevin, senior vice president of Eurofins Genomics, said, “After years of continuous growth within the Eurofins Scientific network, I am extremely happy to align our traditional brands, “MWG”, “Operon” and “Medigenomix”, under a single brand which is synonymous with our commitment to be first-in-class provider of genomic services. This underlines our goal to strengthen our global position as the leading supplier of applied genomics solutions in the future.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important